Sans-de San Nicolàs L., Figueras-Nart I., García-Jiménez I., Bonfill-Ortí M., Guilabert A., Curto-Barredo L., Bertolín-Colilla M., Ferran M., Serra-Baldrich E., Pujol R.M., Santamaria-Babí L.F.. Allergen sensitization stratifies IL-31 production by memory T cells in atopic dermatitis patients. Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1124018. PMID:36993985. IF:5.700(Q1/3D).

Lynde, C, Riedl, E, Maul, JT, Torres, T, Pinter, A, Fabbrocini, G, Daniele, F, Brnabic, A, Reed, C, Wilhelm, S, Holzkamper, T, Schuster, C, Puig, L. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting. ADVANCES IN THERAPY. 2023; 40(3)DOI:10.1007/s12325-022-02379-9. PMID:36515803. IF:3.400(Q2/3D).

Rivera-Diaz, R, Dauden, E, Carrascosa, JM, de la Cueva, P, Puig, L. Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment. Dermatology and Therapy. 2023; 13(3)DOI:10.1007/s13555-022-00881-0. PMID:36635445. IF:3.500(Q1/3D).

Castillo-Regalado E., Ríos R., Aràjol C., Gely C., Márquez L., Calafat M., González-Muñoza C., Cañete F., Mesonero F., Guardiola J., Garcia-Planella E., Mañosa M., Domènech E.. Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy. Gastroenterologia y Hepatologia. 2023; 46(3)DOI:10.1016/j.gastrohep.2022.09.003. PMID:36179946. IF:2.200(Q3/6D).

Rusinol, L, Puig, L. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(4)DOI:10.3390/ijms24043391. PMID:36834806. IF:4.900(Q1/3D).

Iznardo, H, Roe, E, Serra-Baldrich, E, Puig, L. Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis. Pharmaceutics. 2023; 15(2)DOI:10.3390/pharmaceutics15020385. PMID:36839707. IF:4.900(Q1/2D).

Tous-Romero, F, Gimenez-Arnau, AM, Sanz-Sanchez, T, Perez, RG, Carrascosa-Carrillo, JM, Zaragoza-Ninet, V, Cordoba-Guijarro, S, Gatica-Ortega, ME, Miquel-Miquel, J, Borrego-Hernando, L, Ruiz-Gonzalez, I, Serra-Baldrich, E, Silvester-Salvador, JF, Mercader-Garcia, P, Sanchez-Perez, J, Rodriguez-Serna, M, Pastor-Nieto, A, Hervella-Garcia, M, Garcia-Doval, I, Ortiz-de Frutos, FJ. Allergic contact dermatitis to alkyl glucosides: Epidemiological situation in Spain. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(3)DOI:10.1111/jdv.18595. PMID:36153692. IF:8.500(Q1/1D).

Gonzalez-Cao, M, Puertolas, T, Martinez-Vila, C, Carrera, C, Seral, CM, Rodriguez-Jimenez, P, Sequero, S, Cerezuela-Fuentes, P, Ochoa, RF, Munoz, E, Basa, MA, Martin-Liberal, J, Soria, A, Moreno, JFR, Marquez-Rodas, I, Criado, PL, Manzano, JL, Lopez-Castro, R, De Miguel, PA, Villalobos, L, Algarra, SM, Gonzalez-Barrallo, I, Boada, A, Castano, AG, Puig, S, Crespo, G, Fra, PL, Zamora, CA, Rodriguez, MF, Valles, L, Drozdowskyj, A, Gardeazabal, J, Fernandez-Morales, LA, Rodrigo, A, Cruz, R, Yelamos, O, Rubio, B, Mujica, K, Provencio, M, Berrocal, A. SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry. Clinical & Translational Oncology. 2023; 25(3)DOI:10.1007/s12094-022-02985-7. PMID:36566266. IF:2.800(Q2/5D).

Koren J., Lambert, JLW, Thomsen S.F., McAteer H., Fabbrocini G., Corazza V., Jullien D., Augustin M., Warren R.B., de Rie M.A., Lazaridou E., Puig L., Guillevin L., Grosser M., Boehncke, WH. Elevating the Standard of Care for Patients with Psoriasis: 'Calls to Action' from Epicensus, a Multistakeholder Pan-European Initiative. Dermatology and Therapy. 2023; 13(1)DOI:10.1007/s13555-022-00846-3. PMID:36484915. IF:3.500(Q1/3D).

Hernández Fernández C.P., Borrego L., Mercader García P., Giménez Arnau A.M., Sánchez Pérez J., Silvestre Salvador J.F., González Pérez R., Sanz Sánchez T., Sánchez Gilo A., Melé Ninot G., Zaragoza Ninet V., Miquel Miquel F.J., Carrascosa Carrillo J.M., Córdoba Guijarro S., Gatica Ortega M.E., Ruiz González I., Serra Baldrich E., Tous Romero F., Rodríguez Serna M., Pastor Nieto M.A., Pérez Feal P., Hervella Garcés M., de Vega Martínez M., García Doval I.. Sensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC): 2019–2021 epidemiological situation. CONTACT DERMATITIS. 2023; 88(3)DOI:10.1111/cod.14251. PMID:36403138. IF:4.800(Q1/2D).

Yélamos O., Andersen D., Pont M., Iglesias P., Potrony M., Domínguez M., Herrero A., Alejo B., Mateu J., Røpke M., Danneskiold-Samsøe N.B., Malvehy J., Guy R.H., Brix S., Puig S.. Development and validation of a minimally invasive and image-guided tape stripping method to sample atopic skin in children. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2023; 48(2)DOI:10.1093/ced/llac040. PMID:36730521. IF:3.700(Q1/2D).

Puig L.. Psoriasis treatment does not impair the immunogenicity of ChAOx1-S[recombinant] COVID-19 vaccination. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(2)DOI:10.1093/bjd/ljac081. PMID:36763894. IF:11.000(Q1/1D).

Egeberg A., Merola J.F., Schäkel K., Puig L., Mahar P.D., Wang I.Y., Pavo I., Schuster C., Griffiths C.E.M.. Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes. Frontiers in Medicine. 2023; 9DOI:10.3389/fmed.2022.1092688. PMID:36777159. IF:3.100(Q1/2D).

Maravilla-Herrera P., Merino M., Alfonso Zamora S., Balea Filgueiras J., Carrascosa Carrillo J.M., Delgado Sánchez O., Dolz Sinisterra F., García-Ruiz A., Herranz Pinto P., Manfredi A., Martínez Olmos J., Morales de los Ríos Luna P., Puig L., Ros S., Hidalgo-Vega Á.. The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain. Frontiers in Public Health. 2023; 11DOI:10.3389/fpubh.2023.1000776. PMID:36778548. IF:3.000(Q2/3D).

Ryan C., Puig L., Zema C., Thompson E.H.Z., Yang M., Wu E., Bensimon A., Huang X., Joshi A.D., Elewski B.. The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 88(1)DOI:10.1016/j.jaad.2021.12.032. PMID:34954285. IF:12.800(Q1/1D).

Chicharro, P, Llamas-Velasco, M, Armesto, S, Acosta, EH, Vidal, D, Vilarrasa, E, Rivera-Diaz, R, De-la-Cueva, P, Martorell-Calatayud, A, Ballesca, F, Belinchon, I, Carretero, G, Rodriguez, L, Romero-Mate, A, Pujol-Montcusi, J, Salgado, L, Sahuquillo-Torralba, A, Coto-Segura, P, Rodriguez, OB, Feltes, R, Riera-Monroig, J, Dauden, E. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients. Dermatologic Therapy. 2022; 35(12)DOI:10.1111/dth.15929. PMID:36223184. IF:3.600(Q1/3D).

Rusinol, L, Camina-Conforto, G, Puig, L. Biologic treatment of psoriasis in oncologic patients. EXPERT OPINION ON BIOLOGICAL THERAPY. 2022; 22(12)DOI:10.1080/14712598.2022.2152322. PMID:36422998. IF:4.600(Q2/3D).

Lopez-Ferrer, A, Vilarrasa, E, Armesto, S, Santos-Juanes, J, Galache, C, Carretero, G, Sahuquillo, A, Salgado-Boquete, L, del Alcazar, E, Gonzalez-Cantero, A, Martorell, A, Rivera-Diaz, R, Mitxelena-Ezeiza, J, Mateu, A, Belinchon, I, Llamas-Velasco, M, Riera-Monroig, J, Lazaro, A, Lopez-Estebaranz, JL, Gich, I, Puig, L. Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study. Dermatologic Therapy. 2022; 35(11)DOI:10.1111/dth.15831. PMID:36109488. IF:3.600(Q1/3D).

Reolid, A, Armesto, S, Sahuquillo-Torralba, A, Torres, T, Feltes, R, Vilarrasa, E, Belincho, I, de la Cueva, P, Rodriguez, L, Romero-Mate, A, Vidal, D, Coto-Segura, P, Herrera-Acosta, E, Riera-Monroig, J, Salgado, L, Llamas-Velasco, M, Dauden, E. Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2022; 87(3)DOI:10.1016/j.jaad.2022.05.047. PMID:35640798. IF:13.800(Q1/1D).

Piron, M, Jane, M, Ciruela, P, Basile, L, Martinez, A, Puig, L, Bes, M, Sauleda, S. SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain). Blood Transfusion. 2022; 20(5)DOI:10.2450/2022.0232-21. PMID:35175189. IF:3.700(Q2/4D).